Key result
A low-INR anticoagulation strategy in selected aortic valve replacement patients was associated with better 15-year survival compared to standard INR.
Why the study?
Does low-INR anticoagulation improve survival and reduce valve-related events compared to standard anticoagulation in selected patients after aortic valve replacement with a mechanical prosthesis?
Cohort (n=909)
Does low-INR anticoagulation improve survival and reduce valve-related events compared to standard anticoagulation in selected patients after aortic valve replacement with a mechanical prosthesis?
A low-INR anticoagulation strategy (1.5-2.5) in selected patients with a mechanical aortic valve is safe, reducing bleeding without increasing thromboembolic events, and is associated with improved long-term survival.
Answers are grounded in this paper and cite their sources.
Supports low-INR targets in selected mechanical AVR patients; leaves open randomized confirmation before practice change.
OBJECTIVES: To investigate the long-term results of a low international normalized ratio (INR)-anticoagulation program in selected patients after aortic valve replacement (AVR) with the Medtronic Open Pivot mechanical heart valve (OPMHV). METHODS: From January 1993 to December 2012, 909 OPMHV valves were used for single AVR. Patients with preserved sinus rhythm and left ventricular function (Low-INR, n = 552), were managed to an INR of 1.5-2.5 and compared to patients (Standard-INR, n = 357) treated with standard anticoagulation (INR 2.5-3.5). Long-term outcome was analysed for survival and valve-related events, on propensity score matched pairs of 169 patients/group. RESULTS: Within a follow-up cumulating 3096 patient-years, 10- and 15-year survival was significantly better for Low-INR patients: 79% and 63% vs 63% and 34% ( P < 0.001). Multivariate analysis of late mortality identified older age [odds ratio (OR) = 1.05], chronic pulmonary disease (OR = 1.90) and coronary artery disease (OR = 1.57) as patient-related risk factors, and erratic INR (OR = 2.57) as anticoagulation-related factor. The linearized thromboembolic rate was 0.72%/patient-year in Low-INR patients, vs 0.87%/patient-year in Standard-INR patients ( P = 0.59), revealing INR variability as sole predictor (OR 3.54, 95% confidence interval (CI) 1.20-10.51, P = 0.022). The linearized bleeding incidence was respectively 0.61%/patient-year and 1.21%/patient-year for Low-INR and Standard-INR patients ( P = 0.04), retaining older age (OR 1.06, 95% CI 1.02-1.12, P = 0.009), hypertension (OR 2.06, 95% CI 1.00-4.25, P = 0.05) and erratic INR (OR 9.83, 95% CI 5.21-18.56, P < 0.001) as independent risk factors. CONCLUSIONS: This study demonstrated that application of an anticoagulation regimen, aiming a low INR, individualized to selected aortic OPMHV patients, is safe and effective over more than 20 years, without increasing the thromboembolic complication rate while lowering the haemorrhagic events. However, INR variability remains worrisome because of its deleterious effect on outcome.
No takes yet. Share an insight, caveat, or question.
Bové et al. (2017) conducted a cohort in Aortic valve replacement (n=909). Low-INR anticoagulation (INR 1.5-2.5) vs. Standard anticoagulation (INR 2.5-3.5) was evaluated on 15-year survival (p=<0.001). A low-INR anticoagulation strategy in selected aortic valve replacement patients was associated with better 15-year survival compared to standard INR.
Synapse has enriched 10 related papers. Consider them for comparative context: